Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Long-Term Debt Repayments (2022 - 2024)

Coherus Oncology (CHRS) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $85.4 million as the latest value for Q2 2024.

  • Quarterly Long-Term Debt Repayments changed N/A to $85.4 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $85.4 million through Sep 2025, down 24.19% year-over-year, with the annual reading at $233.2 million for FY2025, 10.45% down from the prior year.
  • Long-Term Debt Repayments hit $85.4 million in Q2 2024 for Coherus Oncology, up from $27.2 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $111.1 million in Q1 2022 to a low of -$29.4 million in Q2 2022.